Use of thrombolytic reagents for prevention of vascular disease

Details Use of thrombolytic reagents for prevention of vascular disease Use of thrombolytic reagents for prevention of vascular disease

1996-11-27

1998-11-17

Cintins, Marianne M.

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Peptide containing doai

514 2, A61K 3800

Patent

active

058376887

ABSTRACT:
The present invention relates to the administration of thrombolytic reagents such as tissue plasminogen activator (t-PA), streptokinase and/or urokinase, over prolonged periods of time for prevention of vascular disease such as cerebral vascular thrombosis, pulmonary embolism, deep venous thrombus, acute myocardial infarction and fresh or aged arterial thrombi. The invention relates generally to delivery systems that provide for sustained release of thrombolytic reagents such as tissue plasminogen activator (t-PA), streptokinase and/or urokinase, over prolonged periods of time. The thrombolytic reagents may be administered, for example, transdermally, topically, intranasally or orally.

REFERENCES:
patent: 4853330 (1989-08-01), Goeddel et al.
patent: 5156969 (1992-10-01), Gill et al.
patent: 5262170 (1993-11-01), Anderson et al.
patent: 5288503 (1994-02-01), Wood et al.
patent: 5385732 (1995-01-01), Anderson et al.
patent: 5426097 (1995-06-01), Stern et al.
Bick et al., "Thrombolytic Therapy and Its Uses", Lab .Med. 26:330-337, May 1995.
Shabahang et al., 1994, "The Clinical Impact of Risk Factor and Prophylaxis on Pulmonary Embolism", J. Vasc. Dis. 45:749-754.
Vipond et al., 1994, "Experimental Adhesion Prophylaxis with Recombinant Tissue Ploasminogen Activator", Ann. R. Coll. Surg. Engl. 76:412-415.
Mohr et al., 1988, "Recent Advances in the Management of Venous Thromboembolism", Mayo Clin. Proc. 63:281-290.
Pannekoek et al., 1988, "Mutants of Human Tissue-Type Plasminogen Activator (t-PA): Structural Aspects and Functional Properties", Fibrinolysis 2:123-132.
Rose et al., 1988, "Plasminogen Activators", Ann. Rep. Med. Chem. 23:111-119.
Harris, 1987, "Second-Generation Plasminogen Activators", Prot. Eng. 1:449-458.
Fass and Toole, 1985, "Genetic Engineering and Coagulation Factors", Clin. Haem. 14:547-570.

Affiliated with

Also associated with

Rating

Use of thrombolytic reagents for prevention of vascular disease does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Use of thrombolytic reagents for prevention of vascular disease, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Use of thrombolytic reagents for prevention of vascular disease will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-884538